Bausch Health Companies Inc

Most Recent

  • uploads///teva loss
    Company & Industry Overviews

    Teva Pharmaceutical: Earnings Trends and Recent Developments

    Teva Pharmaceutical’s net income and diluted EPS in the first nine months of 2018 amounted to $541.0 million and $0.53, respectively.

    By Daniel Collins
  • uploads///Bausch
    Company & Industry Overviews

    A Financial Overview of Bausch Health in October

    Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.

    By Daniel Collins
  • uploads///AdobeStock_
    Earnings Report

    Bausch Health Raises Guidance, Shares Follow

    Today, Bausch Health reported its second-quarter earnings results before the market opened. It reported revenue of $2.15 billion in the quarter.

    By Margaret Patrick
  • uploads///change _
    Company & Industry Overviews

    Is Bausch Health Becoming a Successful Turnaround Story?

    Bausch Health (BHC) has gained 20.13% in the last month and is up by 38.93% in 2019 on a YTD basis.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    BHC’s Salix Segment: Xifaxan Drove Its Revenues in Q1

    In the first quarter, Bausch Health Companies (BHC) reported revenues of $445 million for its Salix segment.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    What’s BHC’s Major Revenue Driver in Fiscal 2019?

    In the first quarter, the Bausch + Lomb/International segment reported revenues of $1.12 billion—a rise of 1% YoY on a reported basis.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Bausch Health Companies’ Cash Flow Guidance in Fiscal 2019

    Bausch Health Companies (BHC) has guided for CFO (cash flow from operations) of $1.5 billion–$1.6 billion for fiscal 2019.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Bausch Health Companies Reiterated Its Expense Guidance

    Bausch Health Companies reiterated its adjusted SG&A expense guidance of $2.45 billion and R&D expense guidance of $455 million for fiscal 2019.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Bausch Health Companies Raised Its Earnings Guidance

    Bausch Health Companies (BHC) raised its fiscal 2019 adjusted EBITDA guidance from $3.35 billion–$3.50 billion to $3.40 billion–$3.55 billion.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    BHC: Higher Revenue Guidance for Fiscal 2019

    Bausch Health Companies raised its fiscal 2019 revenue guidance from $8.30 billion–$8.50 billion to $8.35 billion–$8.55 billion.

    By Margaret Patrick
  • uploads///dices over newspaper profit
    Earnings Report

    BHC: Analysts’ Recommendations after Q1 Results

    On May 6, Bausch Health Companies (BHC) reported its first-quarter results. The company reported revenues of $2.02 billion in the first quarter.

    By Margaret Patrick
  • uploads///fall _
    Consumer

    Bill Ackman Is Making a Strong Comeback in 2019

    A large part of Pershing Square’s outperformance year-to-date has come from Chipotle Mexican Grill.

    By Anuradha Garg
  • uploads///pills _
    Company & Industry Overviews

    Analysts Reduce Target Price for Bausch Health Companies in March

    Wall Street analysts expect an upside potential of 24.28% for Bausch Health Companies (BHC) based on the company’s closing price on March 22.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    BHC or TEVA: Who Is Expected to Report Faster EPS Growth?

    In its fourth-quarter earnings conference call, Bausch Health Companies (BHC) has guided for fiscal 2019 non-GAAP adjusted EBITDA of $3.35 billion to $3.50 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    BHC or Teva: Who Is Expected to Report Faster Revenue Growth?

    In its fourth-quarter earnings conference call, Bausch Health Companies ( BHC) guided for fiscal 2019 revenues in the range of $8.30 billion to $8.50 billion, which implies a YoY organic growth of 0% to 3%.

    By Margaret Patrick
  • uploads///about _
    Company & Industry Overviews

    What Analysts Are Recommending for Bausch Health and Teva

    Since its fourth-quarter earnings release on February 20, Bausch Health Companies stock has fallen 8.06%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Bausch Health’s Key Growth Drivers in 2019?

    In its fourth-quarter earnings conference call, Bausch Health Companies (BHC) has highlighted its Bausch + Lomb/International segment and Salix segment as the key growth drivers for the company in fiscal 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    BHC and Teva: How Tax Rate, Interest Expenses, and Capex Stack Up

    In its fourth-quarter earnings investor presentation, Bausch Health Companies (BHC) has guided for a non-GAAP adjusted tax rate of 10% for fiscal 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    BHC and Teva: How Free Cash Flow and Net Debt Stack Up

    Bausch Health Companies (BHC) and Teva Pharmaceutical (TEVA) reported free cash flow of $1.27 billion and $1.79 billion, respectively, in fiscal 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    BHC or Teva: Who Is Controlling Expenses Better?

    In its fourth-quarter earnings investor presentation, Bausch Health Companies (BHC) guided for adjusted non-GAAP SG&A (selling, general, and administrative) expenses of $2.45 billion.

    By Margaret Patrick
  • uploads///Losing Bets
    Consumer

    How Is Ackman Redeeming Himself after Herbalife and Valent?

    Pershing Square had a series of disappointing years, with losses of 20.5%, 13.5%, 4%, and 0.7%, respectively, in 2015, 2016, 2017, and 2018.

    By Anuradha Garg
  • uploads///Graph
    Company & Industry Overviews

    What Are Bausch Health’s Core Growth Drivers for Next Five Years?

    Bausch Health (BHC) has categorized seven of its most promising assets, which involve both recently launched and commercialized products as well as late-stage pipeline products.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bausch Health: Strong Cash Flow Trends in Fiscal 2018

    Bausch Health (BHC) generated cash from operations of $522 million in the third quarter, a YoY rise of 6.53%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bausch Health’s Debt Reduction Strategy

    Bausch Health (BHC) reported less than $25 billion total debt on its balance sheet as of November 6, almost $7.4 billion lower than that reported by the company in the first quarter of 2016.

    By Margaret Patrick
  • uploads///Teva pharma
    Company & Industry Overviews

    A Financial Overview of Teva Pharmaceutical in December

    In the first nine months of 2018, Teva Pharmaceutical’s net revenue fell 16% YoY (year-over-year) to $14.3 billion from $17.0 billion.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Teva Pharmaceutical Stock Rose More than ~8% on December 26

    On December 26, Teva Pharmaceutical (TEVA) stock closed at $15.82, a rise of ~8.43% from its close of $14.59 on December 24.

    By Daniel Collins
  • uploads///pills _
    Company & Industry Overviews

    Bausch’s Ultra Multifocal Contact Lenses Get FDA Approval

    On December 5, Bausch + Lomb announced that the FDA approved its Ultra multifocal contact lenses for patients with astigmatism.

    By Daniel Collins
  • uploads///AstraZeneca
    Company & Industry Overviews

    Why Has AstraZeneca’s Stock Price Increased in 2018?

    On November 19, AstraZeneca’s (AZN) stock price closed at $40.80, which represents ~5% growth from its closing price of $38.78 on October 31.

    By Daniel Collins
  • uploads///Diversified products
    Company & Industry Overviews

    How Bausch Health’s Diversified Products Segment Has Performed

    Bausch Health’s (BHC) Diversified segment consists of neurology, generics, dentistry, and other drugs.

    By Daniel Collins
  • uploads///Salix
    Company & Industry Overviews

    How Is Salix Pharmaceuticals Positioned in November?

    Bausch Health’s (BHC) wholly owned subsidiary Salix Pharmaceuticals generated revenues of $460.0 million in the third quarter compared to $452.0 million in the third quarter of 2017.

    By Daniel Collins
  • uploads///bausch
    Company & Industry Overviews

    How Bausch Health’s Financials Look in November

    Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017.

    By Daniel Collins
  • uploads///part  Salix
    Company & Industry Overviews

    Update on Salix Pharmaceuticals’ Revenues and Developments

    Salix Pharmaceutical’s gross profit increased from $318.0 million in the second quarter of 2017 to $377.0 million in the second quarter, reflecting ~19.0% YoY growth.

    By Daniel Collins
  • uploads///Diversified
    Company & Industry Overviews

    A Performance Overview of Bausch’s Diversified Products Business

    Bausch Health Companies’ (BHC) Diversified Products segment reported net revenue of $336 million in the second quarter.

    By Daniel Collins
  • uploads///Jublia
    Company & Industry Overviews

    An In-Depth Look at Ortho Dermatologics in August

    Ortho Dermatologics’ Onexton and Zovirax each reported revenue of $8 million in the second quarter.

    By Daniel Collins
  • uploads///Ortho
    Company & Industry Overviews

    A Look at the Performance of Bausch Health’s Ortho Dermatologics

    Bausch Health Companies’ (BHC) wholly-owned subsidiary Ortho Dermatologics generated revenue of $142.0 million in the second quarter.

    By Daniel Collins
  • uploads///BL prod
    Company & Industry Overviews

    An In-Depth Look at Bausch + Lomb and Salix Pharmaceuticals

    In the second quarter, Bausch + Lomb’s Lotemax, PureVision, and Artelac generated revenues of $38 million, $32 million, and $27 million, respectively.

    By Daniel Collins
  • uploads///Salix
    Company & Industry Overviews

    How Is Bausch Health’s Salix Pharmaceuticals Positioned?

    Bausch Health Companies’ (BHC) wholly-owned subsidiary Salix Pharmaceuticals reported revenue of $441 million in the second quarter.

    By Daniel Collins
  • uploads///BL
    Company & Industry Overviews

    A Performance Overview of Bausch + Lomb

    Bausch + Lomb, an international subsidiary of Bausch Health Companies (BHC), generated revenue of $1.21 billion in the second quarter.

    By Daniel Collins
  • uploads///Bausch Health
    Company & Industry Overviews

    A Financial Overview of Bausch Health Companies in August

    Bausch Health Companies reported revenue of $2.1 billion in the second quarter, reflecting a ~5% YoY (year-over-year) fall and a ~3% YoY organic rise.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.